October 27, 2017 09:26 AM EDT
R&D
Pharma

Brush­ing back biosims, a con­fi­dent Ab­b­Vie out­lines a block­buster win­ning streak ahead for Hu­mi­ra

John Carroll

Editor & Founder

While Gilead and Cel­gene were show­ing just how sig­nif­i­cant new pric­ing com­pe­ti­tion can be in de­stroy­ing their fore­cast­ing abil­i­ties, Ab­b­Vie showed up Fri­day morn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Stem cell start­up spun out of George Church’s lab rais­es $75M

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times